Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients

1 Nov 2012

Abstract excerpt

Invasive fungal infections are of great concern in pediatric hematopoietic stem cell transplantation (HSCT) recipients. Voriconazole is usually the drug of first choice for treating or preventing invasive aspergillosis. Optimum trough levels (C(trough)s) are between 1 and 5 mg/liter. It is unclear whether these levels are reached with currently advised pediatric dosing schedules. Between 2007 and 2011, 11...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal resistance and susceptibility
Share to Legionella and Acanthamoeba research
Share to Pneumocystis jirovecii pneumonia detection and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23114771
DOI: 10.1128/aac.01540-12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation PatientsPMID 23114771Read ↗

Possibly Appropriate Maintenance dose of Voriconazole in pediatric patients: a single center observational studySemantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.Semantic proximity Read ↗

Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.Semantic proximity Read ↗

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in childrenSemantic proximity Read ↗

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.Semantic proximity Read ↗

Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.